Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CCR1-Antagonist · 1 trial · 1 indication
EAPP was assessed by a composite parameter, consisting of the reading of the visual analog scale (VAS) and the intake of rescue medication
| Arm | Type | Description |
|---|---|---|
| CCR-1 Receptor Antagonist | EXPERIMENTAL | Subjects received 600 mg (2 x 300 mg tablets) of CCR-1 Receptor Antagonist 3 times daily |
| Placebo | PLACEBO_COMPARATOR | Subjects received placebo corresponding to verum |
| Name | Type | Description |
|---|---|---|
| CCR1-Antagonist (BAY86-5047, ZK811752) | DRUG | Given orally in a dose of 600 mg three times daily over 12 weeks |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Pain associated with proven endometriosis, as determined by diagnostic measures within 24 months prior to start of treatment * Women with cyclic menstrual bleeding- Good general health * Willingness to use a barrier contraceptive method such as condoms but no hormonal contrace...
CCR1-Antagonist is being developed for the treatment of endometriosis, specifically for endometriosis-associated pelvic pain. It is a non-hormonal small molecule therapeutic candidate. Bayer AG is developing it as an alternative approach for managing this condition.
CCR1-Antagonist is being developed by Bayer AG, which trades under the ticker BAYRY. Bayer is the sponsor of the clinical program investigating this non-hormonal small molecule for endometriosis-associated pelvic pain.
CCR1-Antagonist is in Phase 2 clinical development. It has completed one Phase 2 trial, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA for any indication.
CCR1-Antagonist has been studied in one completed Phase 2 trial, NCT00185341, titled "Study to Investigate the Efficacy of a Non-hormonal Drug Against Endometriosis Associated Pelvic Pain." The trial enrolled 110 female participants aged 18 and older across Czechia, Denmark, Finland, France, Netherlands, Spain, and Sweden.
Yes, CCR1-Antagonist is also known as BAY86-5047 and ZK811752. These alternative names refer to the same investigational compound being developed by Bayer AG for endometriosis-associated pelvic pain.
CCR1-Antagonist targets the CCR1 receptor. By blocking this chemokine receptor, the small molecule is designed to modulate inflammatory signaling. This mechanism is being investigated as a non-hormonal approach for treating endometriosis-associated pelvic pain.